What the Virtual Buzz Means for Costs, Science and Jobs
By Trista Morrison
Monday, March 30, 2009
With cash scarce and investors clamoring for cost-savings, virtualization appears to be the new reality for biotech companies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.